The Aurum Institute
Contact

Group Chief Operating Officer

Prof Vinodh Edward

Prof Vinodh Edward

Prof Vinodh Edward is the Group Chief Operating Officer and an executive director and board member of The Aurum Institute. He is a basic sciences researcher and has been involved in clinical research management since 2005. He is highly experienced in working with various international donors and delivering on research and health programs globally.

Prof. Edward is also the founder and CEO of Global Health Innovations (an Aurum Group company). He has been involved in clinical research management since 2005. He is passionate about building clinical research capacity throughout Africa and strives to achieve efficiencies in all facets of research. Prof. Edward is also a co-investigator on a number of clinical trials at Aurum.

Prof. Edward holds a Bachelor of Science degree with majors in Microbiology and Physiology as well as a Doctor of Technology Degree in Biotechnology. He has published in the areas of basic sciences and clinical research. He currently holds the position of Adjunct Associate Professor of Medicine at Vanderbilt University and an honorary position at the University of KwaZulu-Natal. He is the co-chair of the Wits Institutional Biosafety Committee.

Publications

7 publications

From 2025 and 2026

  1. 2026

    A Mixed-Method Evaluation of the Association Between Attitudes Toward Gender-Based Violence and Sexual Behaviors Among Adolescents and Young Adults in Rustenburg, South Africa

    Makkan H, Mlotshwa M, Masibi P, Molefe T, Mthembu F, Maenetje P, et al.

    Also an author: Edward VA

    AIDS Behav. 2026 Jan 9.

    View publication (opens in a new tab)

  2. 2026

    Randomised Trial of a Single Dose of Ad26.COV2.S, BNT162b2 or SARS-CoV-2-rS-PN in Previously Vaccinated and Unvaccinated Adults Living with and without HIV in South Africa: Safety and Immunogenicity

    Govender V, Reddy T, Maenetje P, Beattie T, Adonis T, Nielson T, et al.

    Also an author: Edward V

    The Lancet HIV, 2026; 13, e163-e175.

    View publication (opens in a new tab)

  3. 2025

    Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans

    Willis JR, Prabhakaran M, Muthui M, Naidoo A, Sincomb T, Wu W, et al.

    Also an author: Edward V

    Science. 2025 May 15:eadr8382. Epub ahead of print.

    View publication (opens in a new tab)

  4. 2025

    Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial

    Weld ED, Beattie T, Moodley J, Mapendere M, Salles I, Solans BP, et al.

    Also an author: Edward VA

    Lancet HIV. 2025 May 8:S2352-3018(25)00002-5.

    View publication (opens in a new tab)

  5. 2025

    Assessing Vaccine Confidence Using the Vaccine Hesitancy Scale Among Adolescent Girls and Young Women at Risk of HIV Acquisition Living in Uganda, Zambia, and South Africa

    Kyakuwa N, Ssetaala A, Price MA, Nanvubya A, Abyesiza JM, Basalirwa G, et al.

    Also an author: Edward V

    Vaccines (Basel) 2025; 13.

    View publication (opens in a new tab)

  6. 2025

    Should Digital Interventions for HIV Self-Testing Be Regulated with World Health Organization Prequalification?

    Fischer AE, Lalla-Edward ST, Edward V, Abrahams M, Shankland L, de Wit J

    JMIR mHealth and uHealth 2025; 13: e60276.

    View publication (opens in a new tab)

Latest Stories